| scholarly article | Q13442814 |
| P50 | author | Richard Houlston | Q30106731 |
| Colin Turnbull | Q42854208 | ||
| Amit Sud | Q47125536 | ||
| P2860 | cites work | Germline RAD51C mutations confer susceptibility to ovarian cancer | Q57266552 |
| Evaluation ofRAD50 in familial breast cancer predisposition | Q57266727 | ||
| RAD51C is a susceptibility gene for ovarian cancer | Q57306209 | ||
| Precision Medicine Meets Public Health: Population Screening for BRCA1 and BRCA2 | Q57499876 | ||
| Perspective: The precision-oncology illusion | Q57765633 | ||
| ATM heterozygosity and cancer risk | Q58006398 | ||
| Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families | Q59538895 | ||
| Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. | Q64964658 | ||
| Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients | Q80050907 | ||
| Risky business: getting a grip on BRIP | Q87381658 | ||
| p.Val804Met, the Most Frequent Pathogenic Mutation in RET, Confers a Very Low Lifetime Risk of Medullary Thyroid Cancer | Q88201782 | ||
| Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies | Q24531993 | ||
| PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene | Q24615080 | ||
| Genome-wide association study identifies novel breast cancer susceptibility loci | Q24645441 | ||
| Tumour heterogeneity and the evolution of polyclonal drug resistance | Q26866803 | ||
| The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study | Q27644636 | ||
| The CHEK2 I157T variant and colorectal cancer susceptibility: a systematic review and meta-analysis | Q27692525 | ||
| Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers | Q28067154 | ||
| Mutation of a mutL homolog in hereditary colon cancer | Q28114939 | ||
| A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1 | Q28115843 | ||
| Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland | Q28140600 | ||
| Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations | Q28215462 | ||
| Germline mutations in RAD51D confer susceptibility to ovarian cancer | Q28245028 | ||
| Mutations in BRIP1 confer high risk of ovarian cancer | Q28249514 | ||
| Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer | Q28257360 | ||
| Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene | Q28280022 | ||
| A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer | Q28303909 | ||
| Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer | Q28388006 | ||
| PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS | Q28584533 | ||
| Large-scale genotyping identifies 41 new loci associated with breast cancer risk | Q29416989 | ||
| Genome-wide association study of prostate cancer identifies a second risk locus at 8q24 | Q29614925 | ||
| Identification of the breast cancer susceptibility gene BRCA2 | Q29616290 | ||
| Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations | Q33801478 | ||
| Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility | Q33904964 | ||
| Counselling framework for moderate-penetrance cancer-susceptibility mutations | Q33911135 | ||
| Germline p16 mutations in familial melanoma | Q34059915 | ||
| Overview of model-free methods for linkage analysis | Q34064007 | ||
| Genome-wide association study identifies five new breast cancer susceptibility loci | Q34114293 | ||
| A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes | Q34115258 | ||
| Breast-cancer risk in families with mutations in PALB2 | Q34148873 | ||
| RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability | Q34425705 | ||
| Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology | Q34465792 | ||
| ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles | Q34546389 | ||
| CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer | Q34560743 | ||
| Combined associations of genetic and environmental risk factors: implications for prevention of breast cancer | Q34736112 | ||
| Determinants of Power in Gene-Based Burden Testing for Monogenic Disorders. | Q39469486 | ||
| RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. | Q39670403 | ||
| Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database | Q40221041 | ||
| Implications of polygenic risk for personalised colorectal cancer screening | Q40310422 | ||
| Germline RECQL mutations are associated with breast cancer susceptibility | Q41010238 | ||
| Breast and other cancers in families with ataxia-telangiectasia | Q41456075 | ||
| Targeted sequencing of 36 known or putative colorectal cancer susceptibility genes. | Q41696433 | ||
| Polygenic susceptibility to testicular cancer: implications for personalised health care | Q41905393 | ||
| Inherited variants of MYH associated with somatic G:C-->T:A mutations in colorectal tumors | Q43871566 | ||
| Turning of COGS moves forward findings for hormonally mediated cancers. | Q45941363 | ||
| Association analysis identifies 65 new breast cancer risk loci. | Q45979098 | ||
| Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. | Q46332214 | ||
| Translating Germline Cancer Risk into Precision Prevention | Q46417337 | ||
| Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer | Q46782579 | ||
| Population screening for BRCA1/BRCA2 founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral. | Q47251083 | ||
| Evaluation of a Stratified National Breast Screening Program in the United Kingdom: An Early Model-Based Cost-Effectiveness Analysis | Q47614887 | ||
| Genome-wide association studies of cancer: current insights and future perspectives | Q47900293 | ||
| Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women. | Q48526678 | ||
| Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction. | Q50062417 | ||
| A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. | Q51192784 | ||
| Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population. | Q52603806 | ||
| Genome-wide association studies in cancer. | Q53316917 | ||
| Glutathione-Associated Enzymes In Anticancer Drug Resistance. | Q53802751 | ||
| A recurrent mutation in PALB2 in Finnish cancer families. | Q55043120 | ||
| Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles | Q56625730 | ||
| A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21 | Q57078703 | ||
| A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk | Q57092250 | ||
| Accurate functional classification of thousands ofBRCA1variants with saturation genome editing | Q57201736 | ||
| Polygenic susceptibility to prostate and breast cancer: implications for personalised screening | Q34977428 | ||
| Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients. | Q35198383 | ||
| Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies | Q35221430 | ||
| A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer | Q35248192 | ||
| Massively Parallel Functional Analysis of BRCA1 RING Domain Variants | Q35821029 | ||
| A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects | Q35848518 | ||
| Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families | Q35889909 | ||
| Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer | Q35957703 | ||
| Summarizing polygenic risks for complex diseases in a clinical whole-genome report | Q35990450 | ||
| Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. | Q36058262 | ||
| Gene-panel sequencing and the prediction of breast-cancer risk | Q36175072 | ||
| Prediction of breast cancer risk based on profiling with common genetic variants | Q36583004 | ||
| The BOADICEA model of genetic susceptibility to breast and ovarian cancer | Q36695832 | ||
| Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma. | Q36896204 | ||
| CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls | Q37048943 | ||
| No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing | Q37079859 | ||
| Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing | Q37176931 | ||
| Genetic predisposition to breast cancer: past, present, and future | Q37187786 | ||
| BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk | Q37261138 | ||
| Leveraging premalignant biology for immune-based cancer prevention | Q37304964 | ||
| PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations | Q37353838 | ||
| Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model | Q37378034 | ||
| Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab | Q37410693 | ||
| The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers | Q37578078 | ||
| ClinVar: public archive of relationships among sequence variation and human phenotype | Q37661886 | ||
| Architecture of inherited susceptibility to common cancer | Q37736259 | ||
| Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers | Q37834134 | ||
| The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis | Q38109943 | ||
| Higher-than-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer history. | Q38598304 | ||
| The prevalence of DICER1 pathogenic variation in population databases | Q38651200 | ||
| Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry | Q38687607 | ||
| The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium | Q38793676 | ||
| Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers | Q39437211 | ||
| P2507 | corrigendum / erratum | Publisher Correction: Cancer genetics, precision prevention and a call to action | Q90440058 |
| P433 | issue | 9 | |
| P304 | page(s) | 1212-1218 | |
| P577 | publication date | 2018-08-29 | |
| P1433 | published in | Nature Genetics | Q976454 |
| P1476 | title | Cancer genetics, precision prevention and a call to action | |
| P478 | volume | 50 |
| Q92507373 | Analysis of 153 115 patients with hematological malignancies refines the spectrum of familial risk |
| Q97070156 | Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers |
| Q90315966 | Cancer Variant Interpretation Group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary network |
| Q93159670 | Cancer's global epidemiological transition and growth |
| Q64284828 | Clinical implications of germline mutations in breast cancer genes: RECQL |
| Q92213000 | Epigenetic therapy of myelodysplastic syndromes connects to cellular differentiation independently of endogenous retroelement derepression |
| Q89966674 | Evaluating the Integration of Genomics into Cancer Screening Programmes: Challenges and Opportunities |
| Q91729402 | Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group |
| Q90171492 | Identification of Flap endonuclease 1 as a potential core gene in hepatocellular carcinoma by integrated bioinformatics analysis |
| Q94461679 | MC1R variants and associations with pigmentation characteristics and genetic ancestry in a Hispanic, predominately Puerto Rican, population |
| Q90413979 | Molecular Mechanisms of PALB2 Function and Its Role in Breast Cancer Management |
| Q90171350 | Peridiagnostic and cascade cancer genetic testing |
| Q93172501 | Peroxisome proliferator-activated receptor gamma and BRCA1 |
| Q94562441 | Protein-altering germline mutations implicate novel genes related to lung cancer development |
| Q64055629 | Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms |
| Q91021415 | The impact of artificial intelligence on the current and future practice of clinical cancer genomics |
| Q89705992 | The monogenic basis of human tuberculosis |
| Q92839407 | Traditional Chinese medicine as a cancer treatment: Modern perspectives of ancient but advanced science |
| Q90123910 | Using linkage studies combined with whole-exome sequencing to identify novel candidate genes for familial colorectal cancer |
| Q92660341 | Validation of a Semiautomated Natural Language Processing-Based Procedure for Meta-Analysis of Cancer Susceptibility Gene Penetrance |
| Q97093695 | Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort |
Search more.